Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2881 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Nov 2026, 03:15 UTC
2881
Studies in scope
industry-sponsored, all four open statuses
1386
Recruiting now
open to new participants
545
Lead sponsors
across recruiting studies
Top sites
London 51 Oxford 18 Manchester 17 Birmingham 14 Cambridge 13
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca139 Merck Sharp & Dohme LLC97 Hoffmann-La Roche83 Novartis Pharmaceuticals72 Janssen Research & Development, LLC70 Clear sponsor filter
Site city
London51 Oxford18 Manchester17 Birmingham14 Cambridge13
All 77 cities
Target enrolment
to

Trials with a site in London

51 of 2881 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
AbbVie
Phase 3
520
Plymouth, Edinburgh, London, Portsmouth, Airdrie, Nottingham
2026-11-30
Recruiting
AbbVie
Phase 2
165
Cambridge, Edinburgh, London, Southampton, Norwich
2026-01-23
Recruiting
AbbVie
Phase 2/3
490
London, Manchester
2025-12-10
Recruiting
AbbVie
Phase 3
561
Gloucester, London, Bristol, Liverpool, Newcastle upon Tyne, Sunderland
2025-11-05
Recruiting
AbbVie
Observational
2,795
London, Oxford, Leeds, Wakefield, Belfast, Cardiff, Walsall, Wolverhampton
2025-09-02
Recruiting
AbbVie
Phase 1/2
602
London, Birmingham, Cardiff
2025-06-30
Active, closed
AbbVie
Phase 3
573
London, North Finchley, Glasgow, Manchester, Oxford, Birmingham, Stockport
2025-06-17
Recruiting
AbbVie
Phase 2
110
Cambridge, Exeter, London
2025-05-28
Recruiting
AbbVie
Phase 2
390
London, Oxford, Sutton, Birmingham, Manchester
2025-04-24
Recruiting
AbbVie
Phase 3
420
London, Gillingham, Aberdeen, Leeds, Stockport
2025-02-13
Active, closed
AbbVie
Phase 3
468
Poole, Brighton, London, Thetford, Oxford
2025-02-10
Active, closed
AbbVie
Phase 2
185
London, Oxford, Birmingham, Dundee
2024-12-13
Active, closed
AbbVie
Observational
1,314
Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester
2024-11-26
Recruiting
AbbVie
Phase 2
590
Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff
2024-09-04
Active, closed
AbbVie
Phase 3
699
Plymouth, London, Southampton, Glasgow, Manchester, Newcastle upon Tyne
2024-08-19
Active, closed
AbbVie
Phase 3
111
Cambridge, Sheffield, London, Norwich, Edinburgh
2024-08-08
Active, closed
AbbVie
Phase 3
1,400
Truro, Dunfermline, Gloucester, London, Harrogate, Shoreham-by-Sea, Bristol, Newcastle upon Tyne
2024-06-27
Active, closed
AbbVie
Phase 3
421
Cambridge, Edinburgh, London, Nottingham, Leeds, Manchester
2024-05-19
Active, closed
AbbVie
Phase 2
156
Cambridge, Glasgow, London, Oxford
2024-03-23
Recruiting
AbbVie
Phase 3
110
Sheffield, London, Birmingham
2023-12-11
Active, closed
AbbVie
Phase 3
289
High Wycombe, Cambridge, London, North Finchley, Birmingham, Dudley, Prescot, Stockport
2023-11-15
Active, closed
AbbVie
Phase 3
122
Sheffield, London, Southampton, Birmingham
2023-11-06
Recruiting
AbbVie
Phase 3
1,500
High Wycombe, Brighton, Gloucester, London, Oxford, Harrow, Salford
2023-10-11
Recruiting
AbbVie
Phase 3
90
London
2023-10-02
Active, closed
AbbVie
Phase 3
1,014
Bretton, London, Southampton, Northampton, Londonderry, Luton, Portsmouth
2023-07-25
Active, closed
AbbVie
Phase 3
1,328
London, Southampton, Coventry, Leeds, Bristol, Salford
2023-06-21
Active, closed
AbbVie
Phase 1
135
Cambridge, Leicester, London
2023-06-09
Recruiting
AbbVie
Phase 3
450
London, Gillingham, Aberdeen, Stockport
2023-05-01
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
Leeds, London, Manchester
2023-04-04
Recruiting
AbbVie
Phase 1
210
London, Manchester
2023-03-21
Active, closed
AbbVie
Phase 3
520
Cheltenham, London, Northwood, Southampton, Sutton, Manchester, Swansea
2023-03-15
Active, closed
AbbVie
Phase 2
125
London, Northwood, Nottingham, Taunton, Sutton, Manchester
2022-09-28
Active, closed
AbbVie
Phase 1
34
London
2022-05-17
Recruiting
AbbVie
Phase 3
768
London, Nottingham, Birmingham, Manchester
2022-03-25
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Aylesbury, London, Gloucester, Southampton, Oxford, Leeds, Bradford, Bristol
2022-01-13
Active, closed
AbbVie
Phase 3
132
Exeter, Plymouth, London
2021-07-24
Active, closed
AbbVie
Phase 3
527
Cambridge, Exeter, Edinburgh, London, Southampton, Stevenage, Glasgow, Nottingham
2020-09-30
Active, closed
AbbVie
Phase 3
531
Plymouth, Poole, London, Oxford, Cardiff, Aberdeen, Birmingham, Bristol
2020-09-10
Active, closed
AbbVie
Phase 3
330
London, Lincoln, Great Yarmouth, Birmingham, Edinburgh, Newcastle upon Tyne
2020-08-31
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Plymouth, Leicester, London, Southampton, Blackpool, Liverpool, Wolverhampton
2019-09-06
Active, closed
AbbVie
Phase 3
964
London, Glasgow, Stafford, Manchester, Metropolitan Borough of Wirral, Portsmouth, Torquay
2019-03-25
Active, closed
AbbVie
Phase 3
444
London, Manchester, Metropolitan Borough of Wirral, Torquay
2019-03-07
Active, closed
AbbVie
Phase 3
265
Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth
2018-10-22
Active, closed
AbbVie
Phase 2
270
London, Nottingham, Oxford, Birmingham
2018-10-10
Active, closed
AbbVie
Phase 3
1,242
Cambridge, Exeter, Edinburgh, London, Southampton, Barnsley, Liverpool, Newcastle upon Tyne
2018-08-28
Active, closed
AbbVie
Phase 3
1,533
London, Oxford, Dundee, Glasgow, Leeds
2018-08-09
Active, closed
AbbVie
Phase 3
1,336
Cambridge, Exeter, Hull, Edinburgh, Glasgow, London, Manchester, Oxford
2018-04-09
Active, closed
AbbVie
Phase 3
747
Bath, Warrington, London, Taunton, Prescot, Belfast, Birmingham, Dudley
2018-03-21
Active, closed
AbbVie
Phase 3
950
Bath, Exeter, Basingstoke, London, Glasgow, Birmingham, Huddersfield
2017-01-31
Active, closed
AbbVie
Phase 3
1,629
London, Portsmouth, Warrington
2015-12-01
Active, closed
AbbVie
Observational
1,446
Derby, Sheffield, London, Southampton, Glasgow, Carshalton, Aberdeen, Birmingham
2014-08-28
Rows per page Showing 1–51 of 51
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 November 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,881 studies in total at the last sync on 06 Nov 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 51 of those studies with a site in London that also match the filters currently applied.

How many clinical trials are recruiting in London?

15 of the 51 studies on this page are recruiting new participants as of the 06 Nov 2026, 03:15 UTC sync. A further 1 have not yet opened recruitment, 35 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 51 studies
PhaseStudiesRecruitingShare
Phase 334766.7%
Phase 28415.7%
Phase 1417.8%
Observational315.9%
Phase 1/2112%
Phase 2/3112%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
AbbVie5115
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.